Literature DB >> 21571007

Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome.

Alexia M Thomas1, Nghiem Bui, Deanna Graham, Jennifer R Perkins, Lisa A Yuva-Paylor, Richard Paylor.   

Abstract

INTRODUCTION: Genetic heterogeneity likely contributes to variability in the symptoms among individuals with fragile X syndrome (FXS). Studies in the Fmr1 knockout (KO) mouse model for FXS suggest that excessive signaling through group I metabotropic glutamate receptors (Gp1 mGluRs), comprised of subtypes mGluR1 and mGluR5, may play a role. Hence, Gp1 mGluRs may act as modifiers of FXS. Currently no studies have addressed whether manipulation of mGluR1 activity may alter Fmr1 KO behavioral responses, and only a few have reported the effects of mGluR5 manipulation. Therefore, the goals for this study were to extend our understanding of the effects of modulating Gp1 mGluR activity on Fmr1 KO behavioral responses.
METHODS: The present study determined if genetically reducing mGluR1 or mGluR5 by 50% affects an extensive array of behaviors in the Fmr1 KO.
RESULTS: Reduction of mGluR1 moderately decreased Fmr1 KO activity. Reduction of mGluR5 caused an analgesic response in the Fmr1 KO and decreased active social behavior. Modulation of either mGluR1 or mGluR5 did not significantly alter audiogenic seizures, anxiety- and perseverative-related responses, sensorimotor gating, memory, or motor responses.
CONCLUSIONS: Genetic reduction of mGluR1 or mGluR5 modified a few select Fmr1 KO behaviors, although these modifications appeared to be subtle in nature and/or limited to select behaviors. This may indicate that 50% reduction of either mGluR1 or mGluR5 is insufficient to produce behavioral changes, and therefore, these receptors may not be dominant modifiers of a number of Fmr1 KO behavioral phenotypes.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21571007      PMCID: PMC3142659          DOI: 10.1016/j.bbr.2011.04.049

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  79 in total

1.  Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1.

Authors:  K M Huber; J C Roder; M F Bear
Journal:  J Neurophysiol       Date:  2001-07       Impact factor: 2.714

2.  Thinking about the cerebellum.

Authors:  Mitchell Glickstein
Journal:  Brain       Date:  2006-02       Impact factor: 13.501

3.  Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study.

Authors:  Silvia Mandillo; Valter Tucci; Sabine M Hölter; Hamid Meziane; Mumna Al Banchaabouchi; Magdalena Kallnik; Heena V Lad; Patrick M Nolan; Abdel-Mouttalib Ouagazzal; Emma L Coghill; Karin Gale; Elisabetta Golini; Sylvie Jacquot; Wojtek Krezel; Andy Parker; Fabrice Riet; Ilka Schneider; Daniela Marazziti; Johan Auwerx; Steve D M Brown; Pierre Chambon; Nadia Rosenthal; Glauco Tocchini-Valentini; Wolfgang Wurst
Journal:  Physiol Genomics       Date:  2008-05-27       Impact factor: 3.107

4.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

Review 5.  Fragile-X syndrome: variability of phenotypic expression.

Authors:  J D Bregman; E Dykens; M Watson; S I Ort; J F Leckman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1987-07       Impact factor: 8.829

Review 6.  Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis.

Authors:  Gurpreet K Dhami; Stephen S G Ferguson
Journal:  Pharmacol Ther       Date:  2006-03-06       Impact factor: 12.310

7.  FMRP expression as a potential prognostic indicator in fragile X syndrome.

Authors:  F Tassone; R J Hagerman; D N Iklé; P N Dyer; M Lampe; R Willemsen; B A Oostra; A K Taylor
Journal:  Am J Med Genet       Date:  1999-05-28

8.  The contribution of the cerebellum to mental and social functions in developmental age.

Authors:  D Riva; C Giorgi
Journal:  Fiziol Cheloveka       Date:  2000 Jan-Feb

9.  Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome.

Authors:  Caitlyn H McNaughton; Jisook Moon; Myla S Strawderman; Kenneth N Maclean; Jeffrey Evans; Barbara J Strupp
Journal:  Behav Neurosci       Date:  2008-04       Impact factor: 1.912

Review 10.  Phenotypic variation and FMRP levels in fragile X.

Authors:  Danuta Z Loesch; Richard M Huggins; Randi J Hagerman
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004
View more
  38 in total

1.  Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model.

Authors:  S M Goebel-Goody; E D Wilson-Wallis; S Royston; S M Tagliatela; J R Naegele; P J Lombroso
Journal:  Genes Brain Behav       Date:  2012-04-06       Impact factor: 3.449

Review 2.  Genetic models of sensorimotor gating: relevance to neuropsychiatric disorders.

Authors:  Susan B Powell; Martin Weber; Mark A Geyer
Journal:  Curr Top Behav Neurosci       Date:  2012

Review 3.  The autism diagnosis in translation: shared affect in children and mouse models of ASD.

Authors:  Somer L Bishop; Garet P Lahvis
Journal:  Autism Res       Date:  2011-08-31       Impact factor: 5.216

4.  Double Dissociation of the Roles of Metabotropic Glutamate Receptor 5 and Oxytocin Receptor in Discrete Social Behaviors.

Authors:  Ivana Mesic; Yomayra F Guzman; Anita L Guedea; Vladimir Jovasevic; Kevin A Corcoran; Katherine Leaderbrand; Katsuhiko Nishimori; Anis Contractor; Jelena Radulovic
Journal:  Neuropsychopharmacology       Date:  2015-03-31       Impact factor: 7.853

5.  Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders.

Authors:  Regina Waltes; Eftichia Duketis; Michael Knapp; Richard J L Anney; Guillaume Huguet; Sabine Schlitt; Tomasz A Jarczok; Michael Sachse; Laura M Kämpfer; Tina Kleinböck; Fritz Poustka; Sven Bölte; Gabriele Schmötzer; Anette Voran; Ellen Huy; Jobst Meyer; Thomas Bourgeron; Sabine M Klauck; Christine M Freitag; Andreas G Chiocchetti
Journal:  Hum Genet       Date:  2014-01-19       Impact factor: 4.132

6.  Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

Authors:  S J Bonasera; T R Chaudoin; E H Goulding; M Mittek; A Dunaevsky
Journal:  Genes Brain Behav       Date:  2017-03-29       Impact factor: 3.449

7.  Selective role of the catalytic PI3K subunit p110β in impaired higher order cognition in fragile X syndrome.

Authors:  Christina Gross; Nisha Raj; Gemma Molinaro; Amanda G Allen; Alonzo J Whyte; Jay R Gibson; Kimberly M Huber; Shannon L Gourley; Gary J Bassell
Journal:  Cell Rep       Date:  2015-04-23       Impact factor: 9.423

8.  Genetic reduction of muscarinic M4 receptor modulates analgesic response and acoustic startle response in a mouse model of fragile X syndrome (FXS).

Authors:  Surabi Veeraragavan; Deanna Graham; Nghiem Bui; Lisa A Yuva-Paylor; Jürgen Wess; Richard Paylor
Journal:  Behav Brain Res       Date:  2011-11-23       Impact factor: 3.332

Review 9.  Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Authors:  Elizabeth M Berry-Kravis; Lothar Lindemann; Aia E Jønch; George Apostol; Mark F Bear; Randall L Carpenter; Jacqueline N Crawley; Aurore Curie; Vincent Des Portes; Farah Hossain; Fabrizio Gasparini; Baltazar Gomez-Mancilla; David Hessl; Eva Loth; Sebastian H Scharf; Paul P Wang; Florian Von Raison; Randi Hagerman; Will Spooren; Sébastien Jacquemont
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

10.  Reduced phenotypic severity following adeno-associated virus-mediated Fmr1 gene delivery in fragile X mice.

Authors:  Shervin Gholizadeh; Jason Arsenault; Ingrid Cong Yang Xuan; Laura K Pacey; David R Hampson
Journal:  Neuropsychopharmacology       Date:  2014-07-07       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.